New combo shrinks colon tumors before surgery in early trial
NCT ID NCT05706779
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tests whether giving two targeted drugs (encorafenib and cetuximab) before surgery can shrink tumors in people with a specific genetic mutation (BRAF V600E) in colon or upper rectal cancer. About 30 participants will receive the drug combination for a short time, then have surgery. The goal is to see how many tumors shrink significantly. This approach aims to improve surgical outcomes, but ongoing treatment may still be needed after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu - Hôpital Européen Georges Pompidou
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.